SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment
An Open-label and Multicenter Phase Ib/II Clinical Trial to Evaluate the Safety, Immunogenicity, PK/PD Profile of SS109 and NovoSeven® Following a Single Dose, and the Preliminary Efficacy and Safety of SS109 During On-demand Treatment in Hemophilia Patients With Coagulation Factor VIII or IX Inhibitors
Sponsor: Jiangsu Gensciences lnc.
This PHASE1/PHASE2 trial investigates Hemophilia and Hemophilia A With Inhibitor and is currently completed. Jiangsu Gensciences lnc. leads this study, which shows 6 recorded versions since 2023 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Status: Recruiting → Completed
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Mar 2024 — Jul 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Dec 2023 — Mar 2024 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
▶ Show 1 earlier version
-
Sep 2023 — Dec 2023 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Jiangsu Gensciences lnc.
For direct contact, visit the study record on ClinicalTrials.gov .